M&A Deal Summary

Emergent BioSolutions Acquires Adapt Pharma Operations

On August 28, 2018, Emergent BioSolutions acquired life science company Adapt Pharma Operations for 735M USD

Acquisition Highlights
  • This is Emergent BioSolutions’ 7th transaction in the Life Science sector.
  • This is Emergent BioSolutions’ largest (disclosed) transaction.
  • This is Emergent BioSolutions’ 1st transaction in Ireland.

M&A Deal Summary
Date 2018-08-28
Target Adapt Pharma Operations
Sector Life Science
Buyer(s) Emergent BioSolutions
Deal Type Add-on Acquisition
Deal Value 735M USD
Advisor(s) BofA Securities (Financial)
Mayer Brown (Legal)

Target

Adapt Pharma Operations

Dublin 2, Ireland
ADAPT Pharma, Inc. is solely focused on helping address the opioid overdose and addiction crisis. It distributes NARCAN® (naloxone HCl) Nasal Spray, the major FDA approved emergency treatment for opioid overdose, to health agencies, first responders and retail pharmacies. It also has a development pipeline of potential opioid overdose and addiction treatment options. Emergent is a leader in the development, supply and provision of medical countermeasures for accidental, intentional and naturally occurring public health threats as well as emerging infectious diseases.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Emergent BioSolutions

Gaithersburg, Maryland, United States
Category Company
Founded 1998
Sector Healthcare Services
Employees1,600
Revenue 1.0B USD (2023)
DESCRIPTION

Emergent BioSolutions is a specialty biopharmaceutical company seeking to protect and enhance life by offering specialized products to healthcare providers and governments to address medical needs and emerging health threats. Emergent BioSolutions was founded in 1998 and is based in Gaithersburg, Maryland.

DEAL STATS #
Overall 11 of 11
Sector (Life Science) 7 of 7
Type (Add-on Acquisition) 5 of 5
Country (Ireland) 1 of 1
Year (2018) 2 of 2
Size (of disclosed) 1 of 7
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-08-09 PaxVax

Redwood City, California, United States

PaxVax, Inc. is a fully integrated specialty vaccine company with a mission to develop, manufacture and commercialize innovative vaccines against infectious diseases in a socially responsible manner. PaxVax is based in Redwood City, California.

Buy -
Mergr

Product

Company

Legal